ABCELLERA BIOLOGICS INC (ABCL) Stock Fundamental Analysis

NASDAQ:ABCL • CA00288U1066

3.1 USD
+0.16 (+5.44%)
At close: Feb 13, 2026
3.2 USD
+0.1 (+3.23%)
After Hours: 2/13/2026, 8:00:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

Overall ABCL gets a fundamental rating of 3 out of 10. We evaluated ABCL against 58 industry peers in the Life Sciences Tools & Services industry. ABCL has a great financial health rating, but its profitability evaluates not so good. While showing a medium growth rate, ABCL is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • ABCL had negative earnings in the past year.
  • ABCL had a negative operating cash flow in the past year.
  • In multiple years ABCL reported negative net income over the last 5 years.
  • In multiple years ABCL reported negative operating cash flow during the last 5 years.
ABCL Yearly Net Income VS EBIT VS OCF VS FCFABCL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 0 100M -100M 200M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -12.66%, ABCL is in line with its industry, outperforming 43.10% of the companies in the same industry.
  • ABCL has a Return On Equity (-17.81%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -12.66%
ROE -17.81%
ROIC N/A
ROA(3y)-3.84%
ROA(5y)2.39%
ROE(3y)-5.09%
ROE(5y)2.8%
ROIC(3y)N/A
ROIC(5y)N/A
ABCL Yearly ROA, ROE, ROICABCL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 0 10 -10 -20

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for ABCL so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ABCL Yearly Profit, Operating, Gross MarginsABCL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • ABCL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, ABCL has more shares outstanding
  • ABCL has more shares outstanding than it did 5 years ago.
  • ABCL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
ABCL Yearly Shares OutstandingABCL Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M
ABCL Yearly Total Debt VS Total AssetsABCL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

2.2 Solvency

  • ABCL has an Altman-Z score of 1.27. This is a bad value and indicates that ABCL is not financially healthy and even has some risk of bankruptcy.
  • ABCL has a Altman-Z score of 1.27. This is comparable to the rest of the industry: ABCL outperforms 46.55% of its industry peers.
  • ABCL has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 1.27
ROIC/WACCN/A
WACC10.11%
ABCL Yearly LT Debt VS Equity VS FCFABCL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 0 500M 1B

2.3 Liquidity

  • A Current Ratio of 10.10 indicates that ABCL has no problem at all paying its short term obligations.
  • ABCL's Current ratio of 10.10 is amongst the best of the industry. ABCL outperforms 93.10% of its industry peers.
  • A Quick Ratio of 10.10 indicates that ABCL has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 10.10, ABCL belongs to the best of the industry, outperforming 93.10% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.1
Quick Ratio 10.1
ABCL Yearly Current Assets VS Current LiabilitesABCL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • ABCL shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.56%.
  • ABCL shows a small growth in Revenue. In the last year, the Revenue has grown by 7.16%.
  • The Revenue has been growing by 19.97% on average over the past years. This is quite good.
EPS 1Y (TTM)6.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.76%
Revenue 1Y (TTM)7.16%
Revenue growth 3Y-57.48%
Revenue growth 5Y19.97%
Sales Q2Q%37.62%

3.2 Future

  • ABCL is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.32% yearly.
  • ABCL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 44.85% yearly.
EPS Next Y-22.09%
EPS Next 2Y-14.07%
EPS Next 3Y-11.13%
EPS Next 5Y17.32%
Revenue Next Year12.29%
Revenue Next 2Y11.18%
Revenue Next 3Y9.09%
Revenue Next 5Y44.85%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
ABCL Yearly Revenue VS EstimatesABCL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 100M 200M 300M 400M 500M
ABCL Yearly EPS VS EstimatesABCL Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 0.5 -0.5

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for ABCL. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ABCL. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ABCL Price Earnings VS Forward Price EarningsABCL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ABCL Per share dataABCL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3

4.3 Compensation for Growth

  • A cheap valuation may be justified as ABCL's earnings are expected to decrease with -11.13% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-14.07%
EPS Next 3Y-11.13%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • ABCL does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

ABCELLERA BIOLOGICS INC

NASDAQ:ABCL (2/13/2026, 8:00:00 PM)

After market: 3.2 +0.1 (+3.23%)

3.1

+0.16 (+5.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06
Earnings (Next)02-24
Inst Owners37.61%
Inst Owner Change-11.92%
Ins Owners4.29%
Ins Owner Change-0.29%
Market Cap927.95M
Revenue(TTM)35.32M
Net Income(TTM)-171.68M
Analysts81.43
Price Target10.03 (223.55%)
Short Float %20.37%
Short Ratio11.35
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)9.37%
Min EPS beat(2)-10.38%
Max EPS beat(2)29.13%
EPS beat(4)2
Avg EPS beat(4)11.26%
Min EPS beat(4)-10.38%
Max EPS beat(4)29.86%
EPS beat(8)4
Avg EPS beat(8)4.7%
EPS beat(12)6
Avg EPS beat(12)-140.57%
EPS beat(16)8
Avg EPS beat(16)-100.23%
Revenue beat(2)2
Avg Revenue beat(2)111.14%
Min Revenue beat(2)48.58%
Max Revenue beat(2)173.69%
Revenue beat(4)2
Avg Revenue beat(4)35.69%
Min Revenue beat(4)-44.84%
Max Revenue beat(4)173.69%
Revenue beat(8)3
Avg Revenue beat(8)10.63%
Revenue beat(12)3
Avg Revenue beat(12)-3.37%
Revenue beat(16)6
Avg Revenue beat(16)1.83%
PT rev (1m)0%
PT rev (3m)5.9%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-12.66%
EPS NY rev (1m)0%
EPS NY rev (3m)-7.92%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-9.64%
Revenue NY rev (1m)0%
Revenue NY rev (3m)7.23%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 26.27
P/FCF N/A
P/OCF N/A
P/B 0.96
P/tB 1.06
EV/EBITDA N/A
EPS(TTM)-0.57
EYN/A
EPS(NY)-0.72
Fwd EYN/A
FCF(TTM)-0.51
FCFYN/A
OCF(TTM)-0.35
OCFYN/A
SpS0.12
BVpS3.22
TBVpS2.93
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -12.66%
ROE -17.81%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-3.84%
ROA(5y)2.39%
ROE(3y)-5.09%
ROE(5y)2.8%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 204.04%
Cap/Sales 137.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.1
Quick Ratio 10.1
Altman-Z 1.27
F-Score5
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)221.53%
Cap/Depr(5y)274.86%
Cap/Sales(3y)163.57%
Cap/Sales(5y)102.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.56%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.76%
EPS Next Y-22.09%
EPS Next 2Y-14.07%
EPS Next 3Y-11.13%
EPS Next 5Y17.32%
Revenue 1Y (TTM)7.16%
Revenue growth 3Y-57.48%
Revenue growth 5Y19.97%
Sales Q2Q%37.62%
Revenue Next Year12.29%
Revenue Next 2Y11.18%
Revenue Next 3Y9.09%
Revenue Next 5Y44.85%
EBIT growth 1Y15.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year25.14%
EBIT Next 3Y6.86%
EBIT Next 5Y5.3%
FCF growth 1Y-122.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-1660.48%
OCF growth 3YN/A
OCF growth 5YN/A

ABCELLERA BIOLOGICS INC / ABCL FAQ

What is the ChartMill fundamental rating of ABCELLERA BIOLOGICS INC (ABCL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to ABCL.


What is the valuation status for ABCL stock?

ChartMill assigns a valuation rating of 0 / 10 to ABCELLERA BIOLOGICS INC (ABCL). This can be considered as Overvalued.


Can you provide the profitability details for ABCELLERA BIOLOGICS INC?

ABCELLERA BIOLOGICS INC (ABCL) has a profitability rating of 1 / 10.


How financially healthy is ABCELLERA BIOLOGICS INC?

The financial health rating of ABCELLERA BIOLOGICS INC (ABCL) is 7 / 10.


Can you provide the expected EPS growth for ABCL stock?

The Earnings per Share (EPS) of ABCELLERA BIOLOGICS INC (ABCL) is expected to decline by -22.09% in the next year.